Study found long-term benefit of nivolumab for advanced melanoma patients

One-third of a group of heavily pretreated patients with advanced melanoma who received nivolumab monotherapy were alive 5 years after starting the drug, a phase I trial showed. Survival plateaued at 34% by 48 months, after which time disease control was maintained. “What it does demonstrate is...
Source: Skin and Allergy News - Category: Dermatology Source Type: news